I. E. Exeni

ABS0322 SWITCHING MECHANISM OF ACTION VS. SECOND TNF INHIBITOR FOLLOWING FAILURE OF A FIRST TNF INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: EXPERIENCE FROM THE BIOBADASAR 3.0 NATIONAL REGISTRY

C.A. Isnardi, M.A. Alfaro, M. Haye Salinas, M. J. Gamba et autres

Background: Cycling versus switching TNF inhibitors in rheumatoid arthritis remains a critical topic of discussion, as these strategies have distinct implications for treatment efficacy, persistence, and patient outcomes following the failure of an initial TNF inhibitor. Objectives: To evaluate, in patients who …

ar (code pays fourni par la source)

POS0916 DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: DATA FROM FIVE COUNTRIES OF LATIN AMERICA

D. Alpizar-Rodriguez, C. A. Isnardi, V. Rivera Terán, I. Laurindo et autres

ar, py (code pays fourni par la source)

POS0974 CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY

J. A. Brigante, Karen Roberts, C. A. Isnardi, G. Gómez et autres

ar (code pays fourni par la source)